Evidence map›Paper›PMID 26406598›Full record

ArticlePloS one2015

High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.

Joshua C Anderson, Christopher D Willey, Amitkumar Mehta, Karim Welaya, Dongquan Chen, Christine W Duarte, Pooja Ghatalia, Waleed Arafat, Ankit Madan, Sunil Sudarshan and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Use of Sildenafil for Glomerular Disease.Journal of the American Society of Nephrology : JASN · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Joshua C AndersonDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Christopher D WilleyDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Amitkumar MehtaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Karim WelayaClinical Oncology Department, University of Alexandria, Alexandria, Egypt.
Dongquan ChenDivision of Preventative Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Christine W DuarteCenter for Outcomes Research and Evaluation (CORE), Maine Medical Center Research Institute (MMCRI), Portland, Maine, United States of America.
Pooja GhataliaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Waleed ArafatClinical Oncology Department, University of Alexandria, Alexandria, Egypt.
Ankit MadanDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Sunil SudarshanDepartment of Urology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Gurudatta NaikDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
William E GrizzleDivision of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Toni K ChoueiriDepartment of Medical Oncology, Kidney Cancer Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America.
Guru SonpavdeDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
University of Alabama at Birmingham · USAlexandria University · EGDana-Farber Cancer Institute · USMaine Medical Center Research Institute · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
NCI NIH HHS P30 CA013148NCI NIH HHS P30CA013148
6 · The paper itself

Abstract

Despite the widespread use of kinase-targeted agents in clear cell renal cell carcinoma (CC-RCC), comprehensive kinase activity evaluation (kinomic profiling) of these tumors is lacking. Thus, kinomic profiling of CC-RCC may assist in devising a classification system associated with clinical outcomes, and help identify potential therapeutic targets. Fresh frozen CC-RCC tumor lysates from 41 clinically annotated patients who had localized disease at diagnosis were kinomically profiled using the PamStation®12 high-content phospho-peptide substrate microarray system (PamGene International). Twelve of these patients also had matched normal kidneys available that were also profiled. Unsupervised hierarchical clustering and supervised comparisons based on tumor vs. normal kidney and clinical outcome (tumor recurrence) were performed and coupled with advanced network modeling and upstream kinase prediction methods. Unsupervised clustering analysis of localized CC-RCC tumors identified 3 major kinomic groups associated with inflammation (A), translation initiation (B), and immune response and cell adhesions (C) processes. Potential driver kinases implicated include PFTAIRE (PFTK1), PKG1, and SRC, which were identified in groups A, B, and C, respectively. Of the 9 patients who had tumor recurrence, only one was found in Group B. Supervised analysis showed decreased kinase activity of CDK1 and RSK1-4 substrates in those which progressed compared to others. Twelve tumors with matching normal renal tissue implicated increased PIM's and MAPKAPK's in tumors compared to adjacent normal renal tissue. As such, comprehensive kinase profiling of CC-RCC tumors could provide a functional classification strategy for patients with localized disease and identify potential therapeutic targets.

Indexed as

Gene Expression ProfilingCarcinoma, Renal CellCluster AnalysisDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedProtein KinasesTreatment OutcomeProtein Kinases

Identifiers

PMID26406598
PMCPMC4583516
OpenAlexW2222356376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.